TUESDAY, March 19, 2019 (HealthDay News) — Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC).
Latest Cancer News
Tecentriq was evaluated in a clinical study involving 403 adults who had received no prior chemotherapy, the FDA said in a news release.
Average survival for those who took the Tecentriq combination was 12.3 months, compared to 10.3 months among those who took the chemotherapy drugs and a placebo.
The newly approved drug is produced by Genentech, based in South San Francisco.
— Scott Roberts
Copyright © 2019 HealthDay. All rights reserved.
CONTINUE SCROLLING FOR NEXT NEWS ARTICLE